82.70
+0.90
+(1.10%)
At close: 1:30:12 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,035,772.00
1,881,875.00
2,398,648.00
1,901,211.00
1,568,637.00
Cost of Revenue
968,401.00
907,478.00
1,080,052.00
989,073.00
754,605.00
Gross Profit
1,067,371.00
974,397.00
1,318,596.00
912,138.00
814,032.00
Operating Expense
850,952.00
818,620.00
904,554.00
744,706.00
687,178.00
Operating Income
216,419.00
155,777.00
414,042.00
167,432.00
126,854.00
Net Non Operating Interest Income Expense
-7,368.00
-4,837.00
-5,792.00
-14,043.00
-2,254.00
Pretax Income
212,427.00
168,711.00
333,409.00
182,652.00
89,406.00
Tax Provision
91,100.00
91,492.00
151,064.00
78,250.00
61,505.00
Net Income Common Stockholders
121,327.00
77,219.00
182,345.00
104,402.00
27,901.00
Diluted NI Available to Com Stockholders
121,327.00
77,219.00
182,345.00
104,402.00
27,901.00
Basic EPS
1.41
0.90
2.13
1.32
0.36
Diluted EPS
1.41
0.90
2.12
1.32
0.36
Basic Average Shares
85,739.00
85,739.00
85,739.00
79,180.00
77,872.00
Diluted Average Shares
85,787.25
85,791.00
85,828.00
79,236.00
77,926.00
Total Expenses
1,819,353.00
1,726,098.00
1,984,606.00
1,733,779.00
1,441,783.00
Net Income from Continuing & Discontinued Operation
121,327.00
77,219.00
182,345.00
104,402.00
27,901.00
Normalized Income
119,615.80
76,377.40
182,407.40
106,074.00
30,657.00
Interest Income
7,187.00
6,520.00
1,793.00
638.00
2,211.00
Interest Expense
14,555.00
11,357.00
7,585.00
14,681.00
4,465.00
Net Interest Income
-7,368.00
-4,837.00
-5,792.00
-14,043.00
-2,254.00
EBIT
226,982.00
180,068.00
340,994.00
197,333.00
93,871.00
EBITDA
396,822.00
350,458.00
504,541.00
340,956.00
178,013.00
Reconciled Cost of Revenue
968,401.00
907,478.00
1,080,052.00
989,073.00
754,605.00
Reconciled Depreciation
169,840.00
170,390.00
163,547.00
143,623.00
84,142.00
Net Income from Continuing Operation Net Minority Interest
121,327.00
77,219.00
182,345.00
104,402.00
27,901.00
Total Unusual Items Excluding Goodwill
2,139.00
1,052.00
-78.00
-2,090.00
-3,445.00
Total Unusual Items
2,139.00
1,052.00
-78.00
-2,090.00
-3,445.00
Normalized EBITDA
394,683.00
349,406.00
504,619.00
343,046.00
181,458.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
427.80
210.40
-15.60
-418.00
-689.00
12/31/2020 - 12/20/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
1762.TW Chunghwa Chemical Synthesis & Biotech Co., Ltd.
33.20
+0.30%
4133.TW Abnova (Taiwan) Corporation
29.80
-1.16%
4162.TWO PharmaEngine, Inc.
95.10
+2.15%
1734.TW Sinphar Pharmaceutical Co.,Ltd.
30.75
+0.33%
6550.TW Polaris Group
43.40
+0.46%
6589.TWO EirGenix Inc.
79.80
+1.01%
4743.TWO Oneness Biotech Co., Ltd.
79.70
+1.66%
3176.TWO Medigen Biotechnology Corp.
32.60
-1.21%
4147.TWO TaiMed Biologics Inc.
86.50
+0.35%
1733.TW Apex Biotechnology Corp.
29.95
0.00%